

BIONETICS

MUTAGENIC EVALUATION OF COMPOUND FDA 73-52 INOSITOL

5516 Numerson Lane Kenscrigton, Maryland 20795

MUTAGENIC EVALUATION OF COMPOUND FDA 73-52 INOSITOL

SUBMITTED TO

FOOD & DRUG ADMINISTRATION
DEPARTMENT OF HEALTH, EDUCATION AND WELFARE
ROCKVILLE, MARYLAND

SUBMITTED BY

LITTON BIONETICS, INC. 5516 NICHOLSON LANE KENSINGTON, MARYLAND

DECEMBER 17, 1974



TABLE OF CONTENTS

		Page No.
Evalua	tion Summary	1
I.	Objective	. 2
II.	Materials	. 2
III.	Methods	. 3
IV.	Solubility Properties	7
٧.	Toxicity and Dosage Determinations	. 8
VI.	Non-activation Plate Tests	9
VII.	Activation Plate Tests	. 11
VIII.	Non-activation Suspension Tests/Salmonella	17
IX.	Activation Suspension Tests/Salmonella	19
X.	Non-activation Suspension Tests/Saccharomyces	25
XI.	Activation Suspension Tests/Saccharomyces	27
XII.	Summary of Test Results	35
XIII.	Interpretation and Conclusions	
Append	ix - Summary of Tests Evaluating DMSO for Genetic	•



EVALUATION SUMMARY

Compound FDA 73-52, Inositol, did not exhibit genetic activity in any of the $\underline{\text{in vitro}}$ assays included in this evaluation.

DATE: 12-17-74

SPONSOR: Food and Drug Administration, Contract Number 223-74-2104

SUBJECT: Mutagenic Evaluation of Compound FDA 73-52

I. OBJECTIVE

The objective of this study was to assess the genetic activity of the test material in microbial assays with and without the addition of mammalian metabolic enzyme preparations.

II. MATERIALS

A. Test Material

Inositol
A.E. Staley #E910

B. Tissue Homogenates and Supernatants

The tissue homogenates and 9,000 x g supernatants were prepared from liver, lung and testes of the following mammalian species: Mouse - ICR random bred adult males; rat - Sprague-Dawley adult males; and primate - Macaca mulatta adult males.

C. Indicator Organisms

The indicator organisms used for all tests are described below:

- Saccharomyces cerevisiae, strain D4: α ade 2-2 try 5-12 a, ade 2-1, try 5-27
- <u>Salmonella</u> <u>typhimurium</u>, strains:

```
TA-1535; hisG, uvrB, rfa (missense mutation)
TA-1537; hisC, uvrB, rfa ( - frameshift mutation)
TA-1538; hisD, uvrB, rfa ( + frameshift mutation)
```

D. Reaction Mixture

The following reaction mixture was employed in the activation tests:



	Component	Final Concentration/ml
1.	TPN (sodium salt)	6 µМ
2.	Isocitric acid	49 µM
3.	Tris buffer, pH 7.4	28 µM
4.	MgC12	1.7 µM -
5.	I soc itric dehydrogenase	1.0 Unit
6.	Tissue homogenate or cell fraction	72 mg

Components 1-4 were combined and frozen as a "core" reaction mixture to which the other components were added just prior to use.

E. Positive Control Compounds

Table 1 lists chemicals for positive controls in the direct and activation assays.

TABLE 1

POSITIVE CONTROLS USED IN DIRECT AND ACTIVATION ASSAYS

ASSAY	<u>CHEMICAL^a</u>	SOLVENT	PROBABLE MUTAGENIC SPECIFICITY b
Non-activation	Ethylmethane sulfonate	Water or saline	BPS
	2-Nitrosofluorene	Dimethy lsulfoxide ^C	FS
	Quinacrine or Quinacrine mustard	Water or saline	FS
Activation	Dimethylnitrosamine	Water or saline	BPS
	2-Acetylaminofluorene	${\tt Dimethylsulfoxide}^{\tt C}$	FS

^a Concentrations given in the Results Section.

III. METHODS

A. <u>Toxicity</u>

The solubility, toxicity and doses for all chemicals were determined prior to screening.

Each chemical was tested for survival against strains TA-1537 and D4 over a range of doses to determine the 50% survival dose. Bacteria were tested in phosphate buffer, pH 7.4, for one hour at 37°C on a shaker. Yeasts were tested in phosphate buffer, pH 7.4, for four hours at 30°C on a shaker. The 50% survival dose was determined from the survival curve and the 1/4 and 1/2 50% doses calculated.



b BPS = base-pair substitution; FS = frameshift.

^C Previously shown to be non-mutagenic

If no toxicity was obtained for a chemical with a given strain, then a maximum dose of 5% (w/v) was used against the strain.

Unless otherwise specified, the doses calculated for the tests in buffer were applied to the activation tests. The solubility of the test chemical under treatment conditions is stated in the Results Section.

B. Plate Tests

Only three bacteria strains were tested in qualitative plate tests. In the non-activation procedure, approximately 10^9 cells of a log phase culture of the bacterial indicator strains were spread over the surface of a minimal plate, and a measured amount of the test chemical was placed in the center of the test plate. In activation tests, the test chemical was added to the cells, and an aliquot of the mixture was spread on the surface of the test plate. The reaction mixture (0.1 ml) plus tissue extract was then spotted on the surface of the plate. Positive and solvent controls were included. All plates were incubated at 37° C for four days and then scored. Each compound (Test, Positive Control and Solvent Control) was done in duplicate. The results were scored as + or -. Concentrations of the positive control compounds are listed in the Results Section.

C. Suspension Tests

1. Non-activation

Log-phase bacteria and stationary-phase yeast cultures of the indicator organisms were grown in complete broth, washed and resuspended in 0.9% saline to densities of 1 \times 109 cells/ml and 5 \times 107 cells/ml, respectively. This constituted the working stock for tests of a group of test chemicals and their respective controls. Tests were conducted in 30 ml plastic tissue culture flasks. Cells plus appropriate volume(s) of the test chemical were added to the flasks to give a final volume of 2 ml. Solvent replaced the test chemical in the negative controls. Treatment was at 30°C for four hours for yeast tests and at 37°C for one hour for bacterial tests. All flasks were shaken during treatment. Following treatment, the flasks were set in ice. Aliquots of cells were removed, diluted in sterile saline (4°C) and plated on the appropriate complete media. Undiluted samples from flasks containing the bacteria were plated on minimal selective medium. Samples from a 10-1 dilution of treated cells were plated on the selected media for enumeration of gene conversion with strain D4. Bacterial plates were scored after incubation for 48 hours at 37°C. The yeast plates were incubated at 30°C for 3-5 days before scoring.

2. Activation

Bacteria and yeast cells were grown and prepared as described in the nonactivation tests except that the cell densities were increased approximately five-fold for working stock suspensions. Measured amounts of the test and



control chemicals plus 0.25 ml of the stock cell suspension were added to a 30 ml plastic tissue homogenate. All flasks (bacteria and yeast) were incubated at 37°C with shaking. The treatment times as well as the dilutions, plating procedures and scoring of the plates were the same as described for non-activation tests.

D. Preparation of Tissue Homogenates and 9,000 x g Cell Fractions

1. Mice

Male mice (sufficient to provide the necessary quantities of organs for testes, lung and liver homogenates) were killed by cranial blow, decapitated and bled. The three organs were immediately dissected from the animal using aseptic techniques and placed in ice-cold 0.25 M sucrose buffered with Tris at pH of 7.4. Upon collection of the desired quantity of organs, they were washed twice with fresh buffered sucrose and completely homogenized with a motor-driven homogenizing unit at 4° C. The whole organ homogenate obtained from this step was divided into two samples. One sample was frozen at -80° C and the other was centrifuged for 20 minutes at 9,000 x g in a refrigerated centrifuge. The supernatant from the centrifuged sample was retained and frozen at -80° C. These two frozen samples were used for the activation studies.

2. Rats

The same procedure as described for mice was used for this mammal.

3. Primates

The liver, lungs and testes were aseptically removed from freshly killed adult male rhesus (M. mulatta) monkeys. Each organ was cut into a number of pieces each sufficient for one week's studies. The tissues were labeled and frozen at -80°C until needed. Tissue homogenates and 9,000 x g supernatants were prepared as described for mice.

E. Data Recording and Reporting

Following the specified incubation periods all population plates were scored by an automatic colony counter and the results from each plate of a set were recorded, in ink, in bound data books. Information necessary for identification of the specific experiment as well as the presence of any contaminant microorganisms was recorded with each set of plate counts. All minimal or other types of selective media plates were hand scored and the results recorded along with the respective population data. For bacteria strains the number of colonies recorded from either the population or selective plates represents that number in 1 ml of test suspension plated. The numbers recorded for the yeast strain D4 represent the number in 0.5 ml of test suspension plated.



Frequencies were mechanically calculated and double checked. All data presented in the Results Section of this report consists of the actual sum of all raw data plate counts and only the frequencies are calculated figures.



IV. SOLUBILITY PROPERTIES OF THE TEST COMPOUND

- 1. NAME OR DESCRIPTION OF TEST COMPOUND: FDA 73-52 Inositol A.E. Staley #E910
- 2. TEST SOLVENT AND DESCRIPTION OF SOLUBILITY
 OF THE TEST CHEMICAL UNDER TREATMENT
 CONDITIONS:
 Stock solutions of this chemical were prepared in phosphate
 buffer, ph 7.4. The compound was completely soluable at all
 treatment concentrations.
- 3. OTHER COMMENTS:

BIONETICS

_	۰.					
- (:	m	1P	'Ot	11	D	

FDA 73-52

Litton BIONETICS

		D 4	TA-1537
	Dose No.	% Concentration	% Concentration
Range of concentrations of	. 1	1	0.1
the test compound used to	2 . 3	2 .	0.5
determine the 50% survival	3	3	1.0
level	4	4	2.5
	5	5	5.0
	Dose No.	% Survival	% Survival
Survival Results	Control	100	100
	1	100	100
Test Date: 8-13-74	2	100	100
	3	100	100
	4	100	100
	5	93	100
	Dose	% Concentration	% Concentration
Concentrations of the test	Plate Test	-	5.0
chemical required for	\$ 50% Survival	-	=
mutagenicity tests	50% Survival		-
	Other	H 5.0	H 5.0
		L 2.5	L 2.5

VI. NON-ACTIVATION PLATE TESTS

DATE: 9-19-74

			TA-1535	TA-1537	TA-1538
Test	Compound	Concentration/plate	T-1 T-2	T-1 T-2	T-1 T-2
PC	EMS	0.05 ml undi- luted chemical	>10 ³ >10 ³		
¥	QM	0.25 mg		56 43	
	NF	0.25 mg			25 31
SC	SALINE	-	3 0	3 4	
· ·	DMSO	<10%			3 5

NOTE: PC = positive control = solvent control

T-1 = trial 1

T-2 = trial 2
EMS = ethyl methanesulfonate
QM = quinacrine mustard
NF = nitrosofluorene DMSO = dimethyl sulfoxide (c) = contamination present

NON-ACTIVATION PLATE TESTS

DATE: 9-19-74

			TA-	1535_	TA-	1537	TA-	1538
Test	Compound	Concentration	T-1	T-2	T-1	T-2	T-1	T-2
TC	FDA 73-52	5.0%	3	2	6	26	2	1

TC = test compound T-1 = trial 1 NOTE:

T-2 = trial 2

(c) = contamination present

PECTES	S: Mouse				DATE: 9-19	-74
), LUIL				TA-1535	TA-1537	TA-1538
Test	0rgan	Compound	Concentration/plate	T-1 T-2	T-1 T-2	T-1 T-2
PC	Li	DMNA	25 μmoles	>10 ² >10 ²		
		AAF	1.25 mg		>10 ² >10 ²	>10 ² >10 ²
	Lu	DMNA	25 µmoles	7 3		
		AAF	1.25 mg		17 18	45 35
	T	DMNA	25 umoles	(c) 5		
		AAF	1.25 mg		23 16	16 13
SC	ė.	DMNA	25 umoles	3 4		
		AAF	1.25 mg		15 19	17 14
	-	Saline	•	3 4		
	-	DMSO	<10%		12 14	15 13

NOTE:

PC

= positive control
= solvent and chemical controls

AAF = 2-acetylaminofluorene DMNA = dimethylnitrosamine

= liver = lung

= testes

T-1 = trial 1

T-2 = trial 2 DMSO = dimethyl sulfoxide (c) = contamination present

ACTIVATION PLATE TESTS

SPECIE	S: Mouse		•			DATE	: 9-	19-7	4	
			-	TA-1	535		537		TA-1	538
Test	Organ	Compound	Concentration	T-1	T-2	T-1	T-2		T-1	T-2
TC	Li	FDA 73-52	5.0%	4	4	14	17		15	27
	Lu	FDA 73-52	5.0%	4	4	8	8		35	35
	T	FDA 73-52	5.0%	3	7	21	28		31	20

NOTE:

TC = test compound
Li = liver
Lu = lung
T = testes T-1 = trial 1T-2 = trial 2

(c) = contamination present

Control of the second of the s

	. D. A				DATE: 9-19-	74
SPECIES	: Kat			TA-1535	TA-1537	TA-1538
Test	Organ	Compound	Concentration/plate	T-1 T-2	T-1 T-2	T-1 T-2
PC	Li	DMNA	25 μmoles	10 ² >10 ²		
		AAF	1.25 mg		>10 ² 30 ²	30 ² > 10 ²
	Lu	DMNA	25 µmoles	2 3		
		AAF	1.25 mg		17 8	28 20
	T	~ DMNA	25 µmoles	3 6	And the second	
	· · · · · · · · · · · · · · · · · · ·	AAF	1.25 mg		7 8	14 9
SC	_	DMNA	25 μmoles	3 4	A CONTRACTOR	
		AAF	1.25 mg		15 19	17 1
	-	Saline	-	3 4		48
		DMSO	<10%		12 14	15 1

PC NOTE:

= positive control
= solvent and chemical controls SC

AAF = 2-acetylaminofluorene DMNA = dimethylnitrosamine

= liver Li

= lung Lu

= testes

T-1 = trial 1
T-2 = trial 2
DMSO = dimethyl sulfoxide
(c) = contamination present



ACTIVATION PLATE TESTS

SPECIES	S: Rat					DATE	: 9-1	9-74	
				TA-1	535	TA-1	537	TA-1	538
Test	Organ	Compound	Concentration	T-1	T-2	T-1	T-2	T-1	T-2
									
TC	Li	FDA 73-52	5.0%	4	4	27	24	23	28
	Lu	FDA 73-52	5.0%	3	5	5	15	23	24
	Ť	FDA 73-52	5.0%	5	5	10	18	24	40

NOTE: TC = test compound Li = liver

Li = liver Lu = lung T = testes T-1 = trial 1 T-2 = trial 2

(c) = contamination present

SPECIES	S: Monkey	<u> </u>			DATE: 9-19	-74
		÷	•	TA-1535	TA-1537	TA-1538
Test	Organ	Compound	Concentration/plate	T-1 T-2	T-1 T-2	T-1 T-2
PC	Li	DMNA	25 μmoles	>10 ² >10 ²		
		AAF	1.25 mg		>10 ² >10 ²	10 ² 10 ²
	Lu	DMNA	25 µmoles	3 4		
	1	AAF	1.25 mg		10-8	13 10
	T	DMNA	25 μmoles	3 3		
		AAF	1.25 mg		10 7	11 11
sc	-	DMNA	25 µmoles	3 4		
	<u></u>	AAF	1.25 mg		15 19	17 14
	***	Saline	- -	3 4		
	_	DMSO	<10%		12 14	15 13

NOTE:

PC = positive control
SC = solvent and chemical controls

AAF = 2-acetylaminofluorene DMNA = dimethylnitrosamine

= liver

= lung

= testes

T-1 = trial 1

T-2 = trial 2 DMSO = dimethyl spiiozide

(c) = contamination present

Project %. 2468

ACTIVATION PLATE TESTS

SPECIE	SPECIES: Monkey							DATE: 9-19-74					
				TA-1535		TA-1	TA-1537		TA-1538				
Test	` Organ	Compound	Concentration	T-1	T-2	T-1	T-2		T-1	T-2			
тс	Li	FDA 73-52	5.0%	4	0	10	13		17	8			
	Lu	FDA 73-52	5.0%	6	3	4	9		14	23.			
	T	FDA 73-52	5.0%	4	3	7	16		18	20			

NOTE:

TC = test compound
Li = liver
Lu = lung
T = testes
T-1 = trial 1
T-2 = trial 2
(c) = contamination present

VIII. NON-ACTIVATION SUSPENSION TESTS WITH SALMONELLA INDICATOR STRAINS: POSITIVE AND SOLVENT CONTROL RESULTS

DATE: 9-8-74

Test	Indicator Strain	Compound	Concentration	Total Cells/ mlx108	his+ Revertants/ ml	his+ Revertants/10 ⁸ Survivors
PC	TA-1535	EMS	0.05 %	2.96	1,790	604.73
	TA-1537	QM	0.01 mg/ml	3.11	911	292.93
	TA-1538	NF	1.25 mg/ml	3.66	266	72.68
sc	TA-1535	SALINE	-	3.27	6	1.83
	TA-1537	SALINE	-	4.66	37	7.94
	TA-1538	DMS0	-	3.01	13	4.32

NOTE: PC = positive control
SC = solvent control

EMS = ethyl methanesulfonate QM = quinacrine mustard
NF = nitrosofluorene
DMSO = dimethyl sulfoxide (c) = contamination present



NON-ACTIVATION SUSPENSION TESTS WITH SALMONELLA INDICATOR STRAINS

DATE: 9-08-74 Indicator Total his+ his+ Cells/mlx108 Compound Concentration Test Strain Revertants/ Revertants/108 Survivors TC TA-1535 2.62 (80) FDA 73-52 Н TC TA-1535 FDA 73-52 L 3.22 (98) 6 1.86 TC TA-1537 FDA 73-52 7.41 (159) 23 Н 3.10 TC TA-1537 FDA 73-52 L 11.49 (247) 46 4.00 TC FDA 73-52 Н 3.06 (102) TA-1538 26 8.50 TC TA-1538 FDA 73-52 2.91 (97) 31 10.65

NOTE: TC = test compound

H = high dose L = low dose

(c) = contamination present

() = percent survival



ACTIVATION SUSPENSION TESTS IX. WITH SALMONELLA INDICATOR STRAINS: POSITIVE AND SOLVENT CONTROL RESULTS

SPE	CIE	S: 1	louse
-----	-----	------	-------

<u> </u>	-~					<u> </u>
DATE:	9-10-74	<u> </u>			Strain TA-15	35
Test	Organ	Compound	Concentration	Total Cells/ mlx108	<u>his</u> + Revertants/ ml	<u>his</u> + Revertants/10 ⁸ Survivors
PC	<u>Li</u>	DMNA	100 μmoles/ml	4.17	4,449	1082,48
	<u>Lu</u>	DMNA	100 μmoles/ml'	2,59	24	9.27
	Ţ	DMNA	100 μmoles/ml	4.14	22	5.31
SC	-	DMNA	100 µmoles/ml	3.37	6	1.78
	÷	SALINE	-	3.84	8	2.08
DATE:	9-23-74				Strain TA-15	37
Test	Organ	Compound	Concentration	Total Cells/ mlx108	his+ Revertants/ ml	<u>his</u> + Revertants/10 ⁸ Survivors
PC	Li	AAF	1.25 mg/ml	4.64	80	17.24
	Lu	AAF	1.25 mg/ml	5.76	10	1.74
	Ţ	AAF	1.25 mg/ml	5.04	22	4.37
SC	-	AAF	1.25 mg/ml	5.24	41	7.82
		DMS0	_	6.01	41	6.82
DATE:	9-24-74	(Repeated	Compounds)		Strain TA-15	38
Test	Organ	Compound	Concentration	Total Cells/ mlx10 ⁸	<u>his</u> + Revertants/ ml	<u>his</u> + Revertants/10 ⁸ Survivors
PC	Li	AAF	1.25 mg/ml	4.26	181	42,49
	<u>Lu</u>	AAF	1.25 mg/ml	2.04	7	3.43
·	T	AAF	1.25 mg/ml	3.55	6	1.70
SC	-	AAF	1.25 mg/ml	1.46	24	16,44
	-	DMS0	•	2.85	37	12.98

NOTE: PC

= positive control
= solvent and chemical controls SC

AAF = 2-acetylaminofluorene DMNA = dimethylnitrosamine

Li = liver = lung = testes

DMSO = dimethyl sulfoxide

(c) = contamination present



ACTIVATION SUSPENSION TESTS WITH SALMONELLA INDICATOR STRAINS

SPECIES	S: Mous	e				<u>.</u>
DATE:	9-10	- 74			Strain TA-15	35
Test	Organ	Compound	Concentration	Total Cells/ mlx10 ⁸	his+ Revertants/ ml	<u>his</u> + Revertants/10 ⁸ Survivors
TC	Li	FDA 73-52	Н	3.46 (90)	17	4.91
			L	3.21 (84)	22	6.85
	Lu	FDA 73-52	Н	(c)1.87 (49)	6 (c)	3.21
			L	2.60 (68)	7	2.69
	T	FDA 73-52	Н	3.96 (103	21	5.30
			L	3.16 (82)	13	4.11
DATE:	9-23-	74			Strain TA-19	537
TC	Li	FDA 73-52	Н	4.26 (71)	15	3.52
			L	2.37 (39)	23	9.71
	Lu	FDA 73-52	Н	4.33 (72)	9 '	2.08
			L	3.69 (61)	21	5.69
	T	FDA 73-52	Н	3.16 (53)	18	5.70
			L	3.08 (51)	40	12.99
DATE:	9-24-	74			Strain TA-1	538
TC	Li	FDA 73-52	Н	3.37 (118	3) 38	11.28
			L	2.70 (95)	32	11.85
	Lu	FDA 73-52	Н	2.74 (96)	22	8.03
			L	2.57 (90)	19	7.39
	T	FDA 73-52	Н	2.66 (93)	27	10.15
			L	2.97 (104) 22	7.41

NOTES: H = high dose L = low dose

TC = test compound Li = liver

Lu = lungT = testes

(c) = contamination present

() = percent survival



ACTIVATION SUSPENSION TESTS WITH SALMONELLA INDICATOR STRAINS: POSITIVE AND SOLVENT CONTROL RESULTS

SPECI	ES: RAT	Γ				
DATE:	9-1	13-74			Strain TA-15	35
Test	Organ	Compound	Concentration	Total Cells/ mlx108	<u>his</u> + Revertants/ ml	<u>his+</u> Revertants/10 ⁸ Survivors
PC	<u>Li</u>	DMNA	100 µmoles/ml	3.83	1,342	350.39
	<u>Lu</u>	DMNA	100 μmoles/ml	4.34	9	2.07
		DMNA	100 μmoles/ml	3.39	15	4.43
SC	-	DMNA	100 μmoles/ml	3.14	5	1.59
	-	SALINE		4.13	7	1.70
DATE:	9-25	-74			Strain TA-15	37
Test	Organ	Compound	Concentration	Total Cells/ mlx108	<u>his</u> + Revertants/ ml	his+ Revertants/10 ⁸ Survivors
PC	<u>Li</u>	AAF	1.25 mg/ml	4.93	146	29.62
	Lu	AAF	1.25 mg/ml	5.15	64	12.43
	7	AAF	1.25 mg/ml	4.87	79	16.22
SC	-	AAF	1.25 mg/ml	6.30	110	17.46
.•		DMS0	_	6.93	67	9.67
DATE:	9-24	-74			Strain TA-153	38
Test	Organ	Compound	Concentration	Total Cells/ mlx108	<u>his</u> + Revertants/ ml	<u>his</u> + Revertants/10 ⁸ Survivors
PC	Li	AAF	1.25 mg/ml	3.26	137	42.02
	<u>Lu</u>	AAF	1.25 mg/ml	3.18	33	10.38
	T	AAF	1.25 mg/ml	2.30	37	16.09
SC	_	AAF	1.25 mg/ml	1.46	24	16.44
		DMSO	-	2.85	37	12.98

NOTE: PC = positive control

SC = solvent and chemical controls

AAF = 2-acetylaminofluorene DMNA = dimethylnitrosamine

Li = liver Lu = lung T = testes

DMSO = dimethyl sulfoxide

Project No. 2468

(c) = contamination present



ACTIVATION SUSPENSION TESTS WITH SALMONELLA INDICATOR STRAINS

SPEC	IES	:	Rat
------	-----	---	-----

SPECIL	J. Nac						
DATE:	9-13-74			Strair	Strain TA-1535		
Test	Organ	Compound	Concentration	Total <u>his</u> Cells/ Revert mlxl0 ⁸ ml	tants/ Revertants/108		
TC	Li	FDA 73-52	Н	3.01 (73) 4	1.33		
. •			L	3.06 (74) 8	2.61		
	Lu	FDA 73-52	Н	3.43 (83) 5	1.46		
			L	2.63 (64) 4	1.52		
	T	FDA 73-52	Н	2.08 (50) 10	4.81		
			L	2.95 (71) 9	3.05		
DATE:	9-25-74			Strai	n TA-1537		
TC	Li	FDA 73-52	Н	6.70 (97) 77	11.49		
. •			L	3.71 (54) 2	9 7.82		
	Lu	FDA 73-52	. Н	4.02 (58) 9	9 24.63		
			L	7.29 (105) 11	5 15.78		
	T	FDA 73-52	Н	3.97 (57) 5	6 14.11		
			L	3.65 (53) 5	4 14.79		
DATE:	9-24-74			Strai	n TA-1538		
TC	Li	FDA 73-52	11	2.76 (97) 3	7 13.41		
, ,			L	3.79 (133) 3	7 9.76		
	Lu	FDA 73-52	11	0.85 (30)	6 7.06		
			L	0.73 (27) 1	3 17.81		
	T	FDA 73-52	Н	1.69 (59)	6 3.55		
			L	2.87 (101) 2	7 9.41		

NOTES: H = high dose L = low dose

TC = test compound

Li = liver Lu = lung T = testes

(c) = contamination present

() = percent survival



ACTIVATION SUSPENSION TESTS WITH SALMONELLA INDICATOR STRAINS: POSITIVE AND SOLVENT CONTROL RESULTS

SPECI		IKEY					
DATE:	E: 10-1-74 Strain TA-1535						
Test	0rgan	Compound	Concentration	Total Cells/ mlx108	his+ Revertants/ ml	<u>his+</u> Revertants/10 ⁸ Survivors	
PC	Li	DMNA	100 μmoles/ml	5.33	1,600	300.19	
	Lu_	DMNA	100 μmoles/ml	5.91	10	1.69	
	T	DMNA	100 μmoles/ml	5.91	5	0.85	
SC		DMNA	100 μmoles/ml	4.24	9	2.12	
		SALINE		5.24	9	1.72	
DATE:	9-25	-74		/	Strain TA-15	37	
Test	Organ	Compound	Concentration	Total Cells/ mlx108	<u>his</u> + Revertants/ ml	<u>his</u> + Revertants/10 ⁸ Survivors	
PC	Li	AAF	1.25 mg/ml	3.90	95	24.36	
	<u>Lu</u>	AAF	1.25 mg/ml	2.95	22	7.46	
	<u>T</u> _	AAF	1.25 mg/ml	5.29	28	5.29	
SC		AAF	1.25 mg/ml	3.18	25	7.86	
		D MS0	-	2.66	15	5.64	
DATE:	10-4	-74			Strain TA-153	38	
Test	Organ	Compound	Concentration	Total Cells/ mlx108	<u>his</u> + Revertants/ ml	<u>his</u> + Revertants/10 ⁸ Survivors	
PC	<u>Li</u>	<u>AAF</u>	1.25 mg/ml	6.50	197	30.31	
	<u>Lu</u>	AAF	1.25 mg/ml	6.87	86	12.52	
	<u>T</u>	AAF	1.25 mg/ml	4.36	69	15.83	
SC		AAF	1.25 mg/ml	4.90	84	17.14	
	-	DMS0	_	5.55	71	12.79	
NOTE:	SC = AAF = DMNA = Li =	2-acetylami dimethylnit liver	l chemical contro nofluorene	ls	(c) = contamin	ation present	
	T =	lung testes dimethyl su	lfoxide		Project N	o. 2468	

BIONETICS

ACTIVATION SUSPENSION TESTS WITH SALMONELLA INDICATOR STRAINS

SPECIES: Monkey

						<u> </u>
DATE:	10-01	- 74			Strain TA-15	535
Test	Organ	Compound	Concentration	Total Cells/ mlx10 ⁸	<u>his</u> + Revertants/ ml	his+ Revertants/10 Survivors
TC	Li	FDA 73-52	Н	4.36 (83) 7	1.61
			L	4.47 (85) 4	0.90
	Lu	FDA 73-52	<u> </u>	(c)4.20 (80) 7	1.67
			L	4.64 (89) 5	1.08
	T	FDA 73-52	Н	4.50 (86	7	1.56
· · · · · · · · · · · · · · · · · · ·			<u>L</u> ′	4.72 (90) 5	1.06
DATE:	9-25-	·74		;	Strain TA-15	537
TC	<u>Li</u>	FDA 73-52	Н	3.59 (13	5) 9	2.51
			L	5.66 (21:	3) 18	3.18
	Lu	FDA 73-52	H	4.85 (182	2) 14	2.90
			<u> </u>	4.72 (17)	7) 14	2.97
	<u>T</u>	FDA 73-52	Н	4.34 (163	3) 18	4.15
			L	4.09 (156	5) 11	2.69
DATE:	10-04	-74		9	Strain TA-15	38
TC	Li	FDA 73-52	H	4.16 (75)	71	17.07
			L	5.01 (90)	75	14.97
	<u>Lu</u>	FDA 73-52	H	7.09 (128	3) 73 _~	10.30
			L	7.37 (133	3) 67	9.09
	T	FDA 73-52	Н	7.50 (135	i) 42	5.60
	- 10° - 11° - 11° - 11° - 11° - 11° - 11° - 11° - 11° - 11° - 11° - 11° - 11° - 11° - 11° - 11° - 11° - 11° -		L	5.47 (99)	81	14.81

NOTES: H = high dose

L = low dose

TC = test compound

Li = liver Lu = lung T = testes

(c) = contamination present

() = percent survival



NON-ACTIVATION SUSPENSION TESTS WITH SACCHAROMYCES INDICATOR STRAIN D4 Χ.

DATE: 9-16-74

				Strai	n D4		
Test	Compound	Concentration	'Total Population Screened ^a	Numbe Conve Ade ⁺	er of rtants ^b Try [†]	Converta 10 ⁵ Sur Ade ⁺	nts Per vivors Try+
PC	EMS	1.0 %	6.94	189	271	27.23	39.05
sc	Saline	_	~ 7.69	27	38	3.51	4.94

NOTE: PC = positive control SC = solvent control EMS = ethyl methanesulfonate

= number x 10⁵ = number at 10⁻¹ dilution (c) = contamination present



NON-ACTIVATION SUSPENSION TESTS WITH SACCHAROMYCES INDICATOR STRAIN D4

DATE: 9-16-74

-1				Strai	n D4		**
Test	Compound	Concentration	Total Population Screened ^a	Numb Conve Ade+	rtants b	Convert 10 ⁵ Su Ade ⁺	ants Per rvivors Try ⁺
TC	FDA 73-52	Н	5.87 (76)	30	24	5.11	4.09
	FDA 73-52	L	6.44 (84)	25	25	3.88	3.88

NOTE: $TC = test \cdot compound$

H = high dose

L = low dose



XI. <u>ACTIVATION SUSPENSION TESTS</u> <u>WITH SACCHAROMYCES INDICATOR STRAIN D4:</u> POSITIVE AND SOLVENT CONTROL RESULTS

DATE: 9-19-74 SPECIES: Mouse Strain D4 Convertants Per Number of Total Convertants^b Ade⁺ Try⁺ 10⁵ Survivors Ade[†] Try[†] **Population** Screeneda Concentration Compound **Organ** Test . 77 15.89 14.92 82 5.16 150 µmoles/ml **DMNA** PC Li 2.64 2.03 4.93 13 10 150 µmoles/ml DMNA Lu 6 2.16 1.18 5.10 11 150 umoles/ml **DMNA** T 3.99 26 3.07 6.51 20 150 µmoles/ml **DMNA** SC

6.47

NOTE: PC = positive control

SALINE

SC = solvent and chemical controls

DMNA = dimethylnitrosamine

Li = liver Lu = lung T = testes

 $a = number \times 10^5$

b = number at 10⁻¹ dilution

(c) = contamination present

Project No. 2468

22

37

< 5.72

3.40



ACTIVATION SUSPENSION TESTS WITH SACCHAROMYCES INDICATOR STRAIN D4

DATE: 9-19-74 SPECIES: Mouse Strain D4 Total Number of Convertants Per Convertants b 10⁵ Survivors **Population** Screened a Ade⁺ Ade⁺ Organ Compound Concentration Try⁺ Try⁺ TC Li FDA 73-52 H 6.13 (95) 25(c) 4.08 18 2.94 L 5.79 (89) 22 19 3.80 3.28

4.24 (66)

6.72(104)

4.42 (68)

6.85 (106)

24

23

29

32(c)

5.66

3.42

6.56

7.31

3.57

3.62

2.77

31

24

16

19(c) 4.67

NOTE: TC = 1

Lu

T

TC = test compound

H = high dose

L = low dose

Li = liver

FDA 73-52

FDA 73-52

Lu = lung T = testes

 $a = number \times 10^5$

 $b = number at 10^{-1} dilution$

Н

L

H

L

(c)= contamination present

()= percent survival



ACTIVATION SUSPENSION TESTS WITH SACCHAROMYCES INDICATOR STRAIN D4: POSITIVE AND SOLVENT CONTROL RESULTS

DATE: 10-18-74 Rat SPECIES: Strain D4 • High Dose Convertants Per Number of Total 10⁵ Survivors Ade[†] Try[†] Convertants^b Population Ade⁺ Try+ Screeneda Concentration Test Organ Compound 9.46 9.84 75 150 µmoles/ml 78 **DMNA** 7.93 PC Li 3.37 27 4.13 150 µmoles/ml 33 DMNA 7.99 Lu 3.43 150 µmoles/ml 36 (c) 31 (c) 3.99 T **DMNA** 9.03 31 (c) 4.81 3.55 150 µmoles/ml 42 (c) 8.74 **DMNA** SC 3.37 6.03 43 (c) 24 7.13 (c) SALINE

NOTE: PC = positive control

SC = solvent and chemical controls

DMNA = dimethylnitrosamine

Li = liver Lu = lung T = testes

 $a = number \times 10^5$

b = number at 10⁻¹ dilution
(c) = contamination present



ACTIVATION SUSPENSION TESTS WITH SACCHAROMYCES INDICATOR STRAIN D4

IES: Ra	ıt		DATE:	10-18	-74		
Hi	igh Dose			Strai	n D4		
Organ	Compound	Total Population Screened ^a	Number of Convertants b Ade Try t		Convertants Per 10 ⁵ Survivors Ade [†] Try [†]		
Li	FDA 73-52	Н	5.81 (81)	37	36	6.37	6.20
		L					
Lu	FDA 73-52	Н	6.08 (85)	26	34	4.28	5.59
		L					
T	FDA 73-52	H	6.16 (86 <u>)</u>	47	33	7,63	5.36
en e	· · · · · · · · · · · · · · · · · · ·	L					
	Hi Organ Li	Li FDA 73-52	High Dose Organ Compound Concentration Li FDA 73-52 H Lu FDA 73-52 H L	High Dose Organ Compound Concentration Li FDA 73-52 H 5.81 (81) Lu FDA 73-52 H 6.08 (85) L	High Dose Organ Compound Concentration Li FDA 73-52 H 5.81 (81) 37 Lu FDA 73-52 H 6.08 (85) 26	High Dose Organ Compound Concentration Li FDA 73-52 H 5.81 (81) 37 36 Lu FDA 73-52 H 6.08 (85) 26 34	High Dose Strain D4 Total Number of Convertants 105 Strain D4 Convertants 10

NOTE:

TC = test compound H = high dose L = low dose

Li = liver

Lu = lung

T = testes

a = number x 10⁵
b = number at 10⁻¹ dilution
(c)= contamination present

()= percent survival



Project	No.	2468
•		

ACTIVATION SUSPENSION TESTS WITH SACCHAROMYCES INDICATOR STRAIN D4: POSITIVE AND SOLVENT CONTROL RESULTS

SPECIES: Rat

DATE: 9-26-74

	1.0.	v Dose		•	Strain	D4		
Test	_	Compound	Concentration	Total Population Screened ^a	Number Conver	er of tants ^b Try [†]	Convertar 10 ⁵ Sur Ade ⁺	nts Per vivors Try ⁺
	Li	DMNA	150 μmoles/ml	5.85	73	70	12.48	11.97
	Lu	DMNA	150 μmoles/ml	5.81	31	11	5.34	1.89
	· T	DMNA	150 μmoles/ml	5.00	32	19	6.40	3.80
SC		DMNA	150 µmoles/ml	5.27	31	23	5.88	4.36
		SALINE	:	5.50	28	20	5.09	3.64

NOTE: PC

= positive control
= solvent and chemical controls

DMNA = dimethylnitrosamine

= liver = lung = testes

a = number x 10⁵
b = number at 10⁻¹ dilution
(c) = contamination present



ACTIVATION SUSPENSION TESTS WITH SACCHAROMYCES INDICATOR STRAIN D4

SPECIES:		Rat		DATE: 9-26-74				
4 <u></u>	1	Low Dose			Strain	n D4		
Test	Organ	Compound	Concentration	Total Population Screened ^a	Numbe Conyer Ade	rtants b	Convert 10 ⁵ Su Ade ⁺	ants Per rvivors Try [†]
TC	Li	FDA 73-52	H					
			L	5.14 (93)	22	12	4.28	2.34
	Lu	FDA 73-52	Н					
			L	5.18 (94)	22	11	4.25	2.12
	T	FDA 73-52	H					
			L	3.53 (64)	16	25(c)	4.53	7.08
			L	3.53 (64)	16	25(c)	4.53	7.0

NOTE:

TC = test compound

H = high dose L = low dose

Li = liver

Lu = lung T = testes

a = number x 10⁵
b = number at 10⁻¹ dilution
(c) = contamination present

()= percent survival



ACTIVATION SUSPENSION TESTS WITH SACCHAROMYCES INDICATOR STRAIN D4: POSITIVE AND SOLVENT CONTROL RESULTS

DATE: 10-22-74 SPECIES: Monkey Strain D4 Convertants Per Number of Total Convertants b 10⁵ Survivors **Population** Ade⁺ Try⁺ Ade⁺ Try⁺ Screeneda Concentration Test Organ Compound 150 umoles/ml Li **DMNA** PC 68 11.56 11.39 67 5.88 150 umoles/ml **DMNA** Lu 5.32 28 5.70 30 5.26 150 µmoles/ml T **DMNA** 6.83 31 40 5.30 5.85 150 µmoles/ml **DMNA** 5.52 SC 27 44 9.00 4.89 SALINE 7.95 8.21 35 34 4.14

NOTE: PC = positive control

SC = solvent and chemical controls

DMNA = dimethylnitrosamine

Li = liver Lu = lung T = testes

 $a = number \times 10^5$

b = number at 10-1 dilution

(c) = contamination present



SPEC	IES: Mo	onkey			DATE:	10-22-	74	• •
					Strain	D4		
Test	O rgan	Compound	Concentration	Total Population Screened ^a			rtants Per Survivors Try [†]	
TC	Li	FDA 73-52	Н	5.48 (132)	28	33	5.11	6.02
		FDA 73-52	· L	7.18 (173)	31(c)	56(c)	4.32	7.80
	Lu	FDA 73-52	Н	4.17 (101)	32	24	7.67	5.76
		FDA 73-52	L	7.62 (184)	20(c)	95(c)	2.62	12.47
	T	FDA 73-52	Н	4.21 (102)	31	33(c)	7.36	7.82
		FDA 73-52	L	6.74 (163)	25	36	3.71	5.34

NOTE:

TC = test compound H = high dose L = low dose

Li = liver

Lu = lung T = testes

a = number x 10⁵ b = number at 10⁻¹ dilution (c)= contamination present

()= percent survival

XII. SUMMARY OF TEST RESULTS

COMPOUND FDA 73-52

Suspension Tests

Activation				lmonella Rev equencies (x				
<u>Test</u> a	Species ^b	Organ ^C	TA-1535	TA-1537	TA-1538	Ade+	Try+	
NA-PC NA-NC	- -	-	604.73 1.83	292.93 7.94	72.68 4.32	27.23 3.51	39.05 4.94	
NA-H NA-L	-	-	1.91 1.86	3.10 4.00	8.50 10.65	5.11 3.88	4.09 3.88	
A-NC (-C) A-NC (+C) A-PC A-PC A-PC	- M M M	- Li Lu T	2.08 1.78 1082.48 9.27 5.31	6.82 7.82 17.24 1.74 4.37	12.98 16.44 42.49 3.43 1.70	5.72 3.07 15.89 2.64 2.16	3.40 3.99 14.92 2.03 1.18	
A-H A-L A-H A-L A-H A-L	M M M	Li Lu T	4.91 6.85 3.21 2.69 5.30 4.11	3.52 9.71 2.08 5.69 5.70	11.28 11.85 8.03 7.39 10.15	4.08 3.80 5.66 3.42 6.56	2.94 3.28 7.31 3.57 3.62	

a NA = non activation

NC = negative control PC = positive control

= activation

H = high dose
L = low dose

= mouse = monkey

= rat

C Li = liver

Lu = lung T = testes

(-C) = solvent control
(+C) = chemical control

Project 2468

3 LL

COMPOUND FDA 73-52

B. Plate Tests

	<u>Activa</u>	tion	<u>Salmonella Responses</u>				
<u>Test^a</u>	Species ^b	Organ ^C	·····	TA-1535	TA-1537	TA-1538	
NA-PC NA-NC	-	- -	•	+	+	+ -	
NA-H	- .	-		-	-	-	
A-NC (-C) A-NC (+C)	-	<u>.</u>		-	<u>-</u>		
A-PC A-PC A-PC	M M M	Li Lu T		+	+	+ - -	
А-Н	M	Li		-	-	-	
A-H	M	Lu		-	-	-	
А-Н	М	T		-	• •	-	
NC = negat	dose	b _M Mo R	= mouse = monkey = rat	C Li Lu T	= liver = lung = testes	(-C) = solvent control (+C) = chemical contro	

Project . 2468

Suspension Tests

Activation			Salm <u>Fre</u> c	Salmonella Reversion Saccharomyces E Frequencies (x 10 ⁻⁸) Frequencies			yces D4 Co ncies (x	$(x 10^{-5})$	
Test ^a	Species ^b	Organ ^C	TA-1535	TA-1537	TA-1538		Ade+		Try ⁺
NA-PC NA-NC	-	-	•						•
NA-H NA-L	-	- -							
A-NC (-C) A-NC (+C) A-PC A-PC A-PC	- - R R R	- - Li Lu T	1.70 1.59 350.39 2.07 4.43	9.67 17.46 29.62 12.43 16.22	12.98 16.44 42.02 10.38 16.09	L 5.09 5.88 12.48 5.34 6.40	H 6.03 4.81 9.84 4.13 3.99	L 3.64 4.36 11.97 1.89 3.80	H 3.37 3.55 9.46 3.37 3.43
A-H A-L A-H A-L A-H A-L	R R R R R	Li Lu T	1.33 2.61 1.46 1.52 4.81 3.05	11.49 7.82 24.63 15.78 14.11 14.79	13.41 9.76 7.06 17.81 3.55 9.41	4. 7.		2. 5. 2. 5.	20 34 59 .12 .36
NC = PC = A = H =	non activati negative cor positive cor activation high dose low dose	itrol	b M = mouse Mo = monkey R = rat	C L. Li T			(-C) = ((+C) = (solvent co chemical o	ontrol control

Project 2468

B. Plate Tests

	Activa	tion		Salmonella Responses				
Test ^a	Speciesb	Organ ^C		TA-1535	TA-1537	TA-1538		
NA-PC NA-NC	-	-	,					
NA-H	-	-						
A-NC (-C) A-NC (+C)		72			-			
A-PC A-PC A-PC	R R R	Li Lu T		+ - -	+	+ - -		
А-Н	R	Li		-	-	-		
A~H	R	Lu		•	-	•		
А-Н	R	T		-	-	-		
NC = negat	dose	b M Mo R	= mouse = monkey = rat	C Li Lu T	= liver = lung = testes	(-C) = solvent control (+C) = chemical control		

Project <u>. 2468</u>

_		
Α.	Suspension	Tests
, , .	Juspension	1

Activation			monella Rev quencies (x	Saccharomyces D4 Conversion Frequencies (x 10 ⁻⁵)			
Testa	Species ^b	Organ ^C	TA-1535	TA-1537	TA-1538	Ade+	Try+
NA-PC NA-NC	- -	-					
NA-H NA-L	-	- -					
A-NC (-C) A-NC (+C) A-PC A-PC A-PC	- - Mo Mo Mo	- Li Lu T	1.72 2.12 300.19 1.69 0.85	5.64 7.86 24.36 7.46 5.29	12.79 17.14 30.31 12.52 15.83	8.45 5.52 11.56 5.70 5.30	8.21 9.00 11.39 5.32 6.84
A-H A-L A-H A-L A-L	Mo Mo Mo Mo Mo	Li Lu T	1.61 0.90 1.67 1.08 1.56 1.06	2.51 3.18 2.90 2.97 4.15 2.69	17.07 14.97 10.30 9.09 5.60 14.81	5.11 4.32 7.67 2.62 7.36 3.71	6.02 7.80 5.76 12.47 7.82 5.34
NC = n PC = p A = a H = h	non activation active consistive consistive consistive consistive consistivation of the	trol	b M = mouse Mo = monkey R = rat	C Li Lu T	= liver = lung = testes	(-C) = solve (+C) = chem	ent control ical control

Project <u>2468</u>

B. Plate Tests

	Activa	tion		Sali	monella Respon	ses
<u>Test^a</u>	Speciesb	Organ ^C		TA-1535	TA-1537	TA-1538
MA-PC NA-NC	- -	- -	•	·		
NA-H	-	-				
A-NC (-C) A-NC (+C)	-	<u>-</u>		-	-	-
A-PC A-PC A-PC	Mo Mo Mo	Li Lu T		- + -	+	+ -
А-Н	Мо	Li		_	-	-
А-Н	Мо	Lu		-	-	•
А-Н	Мо	T		-	-	-
NC = negat PC = posit		b M Mo R	= mouse = monkey = rat	C Li Lu T	= liver = lung = testes	(-C) = solvent control (+C) = chemical contro
						Project <u>2468</u>

XIII. INTERPRETATION AND CONCLUSIONS

Compound FDA 73-52, Inositol, was evaluated for genetic activity in a series of in vitro microbial assays with and without metabolic activation. The following results were obtained.

A. Salmonella typhimurim

1. Plate Tests

At a concentration of 5.0% (w/v), this compound was not mutagenic for TA-1535, TA-1537 or TA-1538.

2. Non-activation Suspension Tests

These tests were all negative.

3. Activation Suspension Tests

These tests were all negative. The high dose with rat lung produced an elevated reversion frequency with strain TA-1537. Because this increase was not supported by responses at any other dose levels or the plate tests, it was considered to be aberrant. Part of the problem might also be a result of the low positive control response for TA-1537 in this test.

- B. <u>Saccharomyces cerevisiae</u>
- 1. Non-activation Suspension Tests

These tests were all negative.

2. Activation Suspension Tests

These tests were negative. The low dose with monkey lung showed an elevated response at the tryptophan locus. Because this response was not supported by other tests or by the adenine locus in the same test, the response was considered aberrant.

C. Conclusions

This compound was not genetically active under the test conditions employed in this evaluation.

Submitted by:

David Brusick, Ph.D.

Director

Department of Genetics



<u>APPENDIX</u>

SUMMARY OF TESTS EVALUATING DMSO FOR GENETIC ACTIVITY IN <u>SALMONELLA</u> AND <u>SACCHAROMYCES</u>



COMPOUND DIMETHYSULFOXIDE

Α.	Suspension	n lests

A. Suspension	<u>lests</u> Activat	cion		a Reversion es (x 10 ⁻⁸)	Saccharomyces D4 Conversion Frequencies (x 10 ⁻⁵)		
Test	Speciesa	Organ ^b	TA-1535	TA-1538	Ade ⁺	Try ⁺	
Non-activation	~	-					
Control (-C) High Dose ^C Low Dose ^d	- - -	- - -	0.74 1.91 0.53	0.88 1.05 1.37	32.51 28.32 40.73	4.34 2.95 0.49	
Activation				•			
Control (+C) Control (-C)	-	-	1.80 1.43	0.36 1.04	38.27 37.12	2.47 2.64	
High Dose ^C :	М .М М	Li Lu T	0.34 0.59 0.62	1.07 0.58 0.30	47.77 36.29 34.35	2.75 1.39 1.94	
Lose Dose ^d	M M M	Li Lu T	0.43 0.11	0.87 3.14 0.39	34.02 42.30 45.95	1.18 1.40 2.32	

Note: (-C) = solve	nt control and	(+C) = 1	test chemical	control	wi thout	homogenat	e .	
a M = mouse Mo = monkey	b Li = Lu =	liver lung		Bacteria Yeast	= 3% = 5%		Bacteria Yeast	

COMPOUND DIMETHYSULFOXIDE

B. Plate Tests

	Activa	tion	Salmonella Responses				
Test	Speciesa	Organ ^b	TA-1535	TA-1537	TA-1538		
Non-activation	•						
Control (-C) Test compound (3%)	-	-	-	-	-		
Activation							
Control (+C) Control (-C)	• "	-		- -			
Test compound (3%)	M M M R R R Mo Mo	Li Lu T Li Lu T Li Lu T	-	- - - - - -	- - - - -		
Note: (-C) = solvent c a M = mouse Mo = monkey	control and (+	-	ontrol without homo	ogenate			